0000000001029298

AUTHOR

Lorenza Landi

showing 6 related works from this author

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

2015

Background Cancer stem cells represent a population of immature tumor cells found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer stem cells isolation and in vitro sensitivity assay are feasible in a clinical setting. Methods Cancer stem cells were isolated from effusions or fresh cancer tissue of 23 patients who progressed after standard therapy failure. Specific culture conditions selected for immature tumor cells that express markers of stemness. These cells were exposed in vitro to chemotherapeutic and targeted agents. Results Cancer stem cells were extracted from liver metas…

OncologyMalemedicine.medical_specialtyLung NeoplasmsTime FactorsColorectal cancerTarget therapy drug sensitivity cancer stem cellsPopulationlcsh:MedicineAntineoplastic AgentsDrug resistanceCell SeparationCancer stem cellInternal medicinemedicineHumansIn patienteducationlcsh:ScienceAgedAged 80 and overSettore MED/04 - Patologia Generaleeducation.field_of_studyMultidisciplinaryLungbusiness.industrylcsh:RLiver NeoplasmsMiddle Agedmedicine.diseaseIn vitroClinical trialPleural EffusionDrug Combinationsmedicine.anatomical_structureLymphatic MetastasisNeoplastic Stem CellsFeasibility Studieslcsh:QFemaleDrug Screening Assays AntitumorbusinessColorectal NeoplasmsResearch Article
researchProduct

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the r…

2021

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this issue and to provide a picture of the advancement of anti-HER2 treatments, we performed a large, multicenter, retrospective study of HER2-positive BC patients. Methods: The observational PANHER study included 1,328 HER2-positive advanced BC patients treated with HER2 blocking agents since June 2000 throughout July 2020. Endpoints of efficacy were progression-free survival (PFS) and overall survival (OS). Results: Patients who received a first-l…

Oncologymedicine.medical_specialtyAdvanced breastT-DM1Treatment outcomeLapatinibBreast cancerpertuzumabInternal medicineMedicinelapatinibRC254-282advanced breast cancerbusiness.industryHuman epidermal growth factoradvanced breast cancer; HER2-positive; lapatinib; pertuzumab; sequence; T-DM1Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancersequencemedicine.diseaseHER2-positiveOncologyObservational studyPertuzumabbusinessmedicine.drug
researchProduct

Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC)

2018

// Silvia Vecchiarelli 1, * , Francesco Passiglia 2, * , Armida D’Incecco 3, * , Marianna Gallo 4 , Antonella De Luca 4 , Elisa Rossi 5 , Federica D’Inca 1 , Gabriele Minuti 1 , Lorenza Landi 1 , Chiara Bennati 1 , Michela Spreafico 1 , Manolo D’Arcangelo 1 , Valentina Mazza 1 , Nicola Normanno 4 and Federico Cappuzzo 1 1 Department of Oncology and Hematology, AUSL della Romagna, Ravenna, Italy 2 Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy 3 Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy 4 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy 5 Fond…

0301 basic medicinePD-L1medicine.medical_specialtymedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Gastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerSurvival analysisChemotherapyHematologybusiness.industrybiomarkersBiomarkermedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCohortMann–Whitney U testImmunotherapybusinessNon-small-cell lung cancerResearch PaperProgrammed death
researchProduct

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.

2019

Background: In the field of oncological assistance, nowadays we have to deal with a complex scenario where patients got used to obtain a huge amount of information through internet or social media and to apply them in performing their health-related decisions. This landscape requires that clinicians become able to handle therapeutical approaches and adequate skills in communication tools to satisfy the current needs. Our project aimed to build a communication model based on clinical oncologists’ real experiences in order to find a simple way to share with patients all the innovative therapeutical opportunities today available in lung cancer. The final goal is to design a flexible and person…

Communication Internet Lung cancerCancer ResearchKnowledge managementComputer sciencemedia_common.quotation_subjectContext (language use)Quality of life (healthcare)Nuclear Medicine and ImagingRadiology Nuclear Medicine and imagingActive listeningSocial mediaPeer learningmedia_commonTeamworkbusiness.industryCommunicationCommunication; Internet; Lung cancer; Oncology; Radiology Nuclear Medicine and Imaging; Cancer Researchlung cancerCommunication; lung cancer; internetOncologyModels of communicationThe InternetOriginal ArticleinternetbusinessRadiologyTranslational cancer research
researchProduct

The role of research nurse in translational studies: LUCAS experience

2015

medicine.medical_specialtyOncologyNursingbusiness.industryAlternative medicineMedicineHematologybusinessAnnals of Oncology
researchProduct

sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observati…

2021

Supplemental material, sj-docx-1-tam-10.1177_17588359211059873 for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting by Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D���Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D���Auria, Anna Ceribe…

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct